A new genetic study suggests GLP-1 drugs may support better mental health in addition to managing diabetes and obesity.
- New genetic study links GLP-1 receptor activation to better mental well-being
- Researchers found lower genetic odds of depression and bipolar disorder
- Experts say the findings are promising but not yet ready for clinical use
Scientists have found new genetic evidence suggesting that medications targeting the glucagon-like peptide-1 (GLP-1) receptor, better known as GLP-1 drugs, may do more than help people lose weight or control diabetes.
They may also lower the long-term risk of depression and bipolar disorder, although experts stress that clinical trials are still needed before these medicines can be used to treat mental health conditions.
The findings come from a new Translational Psychiatry study, while earlier reviews and clinical studies have also reported improvements in depressive symptoms among people taking GLP-1 receptor agonists.
Together, the research is expanding interest in whether these widely used metabolic drugs could eventually play a role in mental healthcare (1✔ ✔Trusted Source
Glucagon-like peptide-1 receptor activation and mental health: a drug-target mendelian randomization study
Advertisement
GLP-1 Drugs Linked to Reduced Risk of Depression and Bipolar Disorder
According to a new study published in Translational Psychiatry, lifelong genetic activation of the glucagon-like peptide-1 receptor (GLP-1R) was linked with better mental well-being and significantly lower odds of major depressive disorder and bipolar disorder.
Instead of testing people taking medicines, researchers used a technique called “drug-target Mendelian randomization,” which examines naturally occurring genetic differences that mimic the biological effects of GLP-1 receptor activation. This approach helps scientists understand whether a drug target itself may influence disease risk.
The researchers analyzed genetic data from some of the world’s largest genome-wide association studies, including the UK Biobank, the GIANT consortium, the Psychiatric Genomics Consortium, and the Finnish FinnGen database.
Advertisement
Mental Health Outcomes Linked to GLP-1 Receptor Activation
|
Mental health area |
What the study observed |
|
Depression |
Linked with a lower likelihood of major depressive disorder and fewer depressive symptoms |
|
Bipolar disorder |
Linked with a lower likelihood of bipolar disorder |
|
Overall well-being |
Associated with better life satisfaction and a more positive mood |
|
Positive emotions |
Associated with greater positive affect |
|
Substance use disorders |
Showed possible benefits, but more research is needed |
|
Blood sugar control |
Mental health benefits appeared to be linked more closely to GLP-1 receptor activity than blood sugar lowering alone |
Researchers also observed that the association appeared stronger for depression in women, although the difference between men and women was not statistically significant.
The study found very limited evidence that lowering blood sugar (HbA1c) alone explained these mental health benefits. Instead, the results suggest that GLP-1 receptor activation may influence brain pathways beyond its effects on weight loss and glucose control.
However, the researchers caution that this was not a clinical trial. The analysis reflects lifelong genetic differences rather than the short-term effects of taking medicines such as semaglutide or liraglutide.
They also note that only a small number of genetic variants were available for analysis, meaning larger clinical studies are still required before GLP-1 drugs can be recommended for treating depression or bipolar disorder.
Advertisement
What Are GLP-1 Drugs and Why Are They Being Studied for Mental Health?
GLP-1 receptor agonists are medicines originally developed to treat type 2 diabetes and, more recently, obesity.
Common examples include semaglutide, liraglutide, and dulaglutide.
Scientists have now discovered that GLP-1 receptors are also present in several parts of the brain involved in mood, memory, reward, and emotion.
According to a recent review in Pharmacological Research, GLP-1 drugs may reduce brain inflammation, improve communication between brain cells, and influence important neurotransmitters such as dopamine and serotonin (2✔ ✔Trusted Source
Psychotropic effects of GLP-1R agonists
These effects could explain why researchers are exploring whether the medicines might also benefit conditions such as depression, anxiety, bipolar disorder, and substance use disorders.
The evidence has been gradually building over the past few years. A systematic review published in Current Treatment Options in Psychiatry analyzed 81 human and animal studies and concluded that GLP-1 receptor agonists showed potential benefits for depressive symptoms, anxiety, cognitive function, binge eating, and alcohol or substance use disorders (3✔ ✔Trusted Source
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Researchers say these medicines should not yet be considered mental health treatments. The current findings are encouraging but are still based largely on genetic studies, observational research, and relatively small clinical trials.
How Do GLP-1 Drugs Work?
GLP-1 medicines mimic a natural hormone called glucagon-like peptide-1 (GLP-1). They help the body release insulin when blood sugar rises, slow the emptying of the stomach, reduce appetite, and increase feelings of fullness.
Together, these effects help improve blood sugar control and support weight loss.
What Do Earlier Studies Say About GLP-1 and Depression?
The new findings add to a growing body of research suggesting that GLP-1 receptor agonists may influence mental health as well as metabolic health.
Earlier evidence points in the same direction. A systematic review and meta-analysis published in the American Journal of Geriatric Psychiatry, which analyzed data from 2,071 participants, found that people receiving GLP-1 receptor agonists experienced modest but significant improvements in depression scores compared with placebo or other diabetes medicines (4✔ ✔Trusted Source
The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis
Most participants in these studies had type 2 diabetes, obesity or overweight, indicating that the mental health benefits were observed while the medicines were being used for their approved metabolic conditions.
The authors noted that although the improvements were encouraging, the available clinical studies were relatively small and were not originally designed to treat depression.
They recommended larger, well-designed clinical trials to confirm whether GLP-1 drugs could become part of future mental health treatment.
Can GLP-1 Drugs Be Repurposed for Depression?
Experts say it is too early to prescribe GLP-1 medicines specifically for depression or bipolar disorder.
According to the study, the findings show a genetic association rather than proof that taking GLP-1 medicines will prevent or treat mental illness. Large randomized clinical trials are still needed before doctors can recommend these medicines for psychiatric conditions.
The review also concludes that although early studies are promising, most have involved small groups of patients, different study designs, and short follow-up periods.
More robust trials are needed to determine who may benefit, which medicine works best, and what the long-term mental health effects may be.
The growing popularity of GLP-1 drugs has also raised concerns about inappropriate use.
According to The BMJ, doctors in India have reported a sharp rise in off-label use of GLP-1 medicines for weight loss among people without diabetes, with demand increasing despite high costs and limited medical supervision.
Experts have urged that these medicines should be used only under a doctor’s guidance to protect patient safety (5✔ ✔Trusted Source
India: Doctors report surge in use of off label GLP-1 agonists among rich
Researchers say the latest findings open an exciting new area of research.
While GLP-1 medicines are already transforming diabetes and obesity care, scientists now hope future clinical trials will determine whether they can also become part of treatment strategies for depression, bipolar disorder, and other mental health conditions.
Until then, they should continue to be used only for their approved medical indications.
Frequently Asked Questions
Q: Can GLP-1 drugs help treat depression?
A: Current studies suggest they may reduce the risk of depression, but they are not approved as depression treatments.
Q: What are GLP-1 drugs mainly used for?
A: They are prescribed to manage type 2 diabetes and obesity by improving blood sugar control and promoting weight loss.
Q: Do GLP-1 drugs affect the brain?
A: Yes. Researchers believe they may influence brain inflammation, mood-related chemicals, and nerve cell function, but more studies are needed.
Q: Should healthy people take GLP-1 drugs for mental health?
A: No. Experts do not recommend using these medicines for depression or bipolar disorder outside approved medical indications or clinical trials.
Q: Why are researchers interested in GLP-1 drugs for mental health?
A: Recent genetic studies, clinical reviews and laboratory research suggest these medicines may have effects on brain pathways involved in mood and emotional well-being, but larger clinical trials are still required.
References:
- Glucagon-like peptide-1 receptor activation and mental health: a drug-target mendelian randomization study – (https://www.nature.com/articles/s41398-026-04244-7)
- Psychotropic effects of GLP-1R agonists – (https://www.sciencedirect.com/science/article/pii/S104366182500461X)
- The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review – (https://link.springer.com/article/10.1007/s40501-024-00331-y)
- The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis – (https://www.sciencedirect.com/science/article/pii/S1064748123003949)
- India: Doctors report surge in use of off label GLP-1 agonists among rich – (https://www.bmj.com/content/386/bmj.q1605)
Source-Medindia